Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the safety of combining juxtasclerally administered anecortave acetate 15 mg with triamcinolone acetate 4 mg administered intravitreally following photodynamic therapy with verteporfin for the treatment of exudative age-related macular degeneration (AMD).


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00211419
Study type Interventional
Source Manhattan Eye, Ear & Throat Hospital
Contact
Status Completed
Phase Phase 1

See also
  Status Clinical Trial Phase
Completed NCT00058994 - An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD Phase 3
Completed NCT00417846 - Age-related Macular Degeneration: Detection of Onset of New Choroidal Neovascularization (AMD DOC Study) N/A
Completed NCT00051129 - Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD) Phase 3
Completed NCT01024998 - Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD) Phase 1
Recruiting NCT00331253 - Treatment of Patients With Neovascular AMD Using Indocyanine Green-Mediated Photothrombosis (i-MP). Phase 2